699 related articles for article (PubMed ID: 33774199)
1. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
[TBL] [Abstract][Full Text] [Related]
2. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D; Zhou S; Gao W
ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
[TBL] [Abstract][Full Text] [Related]
3. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines.
Islam W; Fang J; Imamura T; Etrych T; Subr V; Ulbrich K; Maeda H
Mol Cancer Ther; 2018 Dec; 17(12):2643-2653. PubMed ID: 30232144
[TBL] [Abstract][Full Text] [Related]
5. Boosting Nanomedicine Efficacy with Hyperbaric Oxygen Therapy.
Wang X; Li S; Liu X; Wu X; Ye N; Yang X; Li Z
Adv Exp Med Biol; 2021; 1295():77-95. PubMed ID: 33543456
[TBL] [Abstract][Full Text] [Related]
6. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.
Mao C; Li F; Zhao Y; Debinski W; Ming X
Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297
[TBL] [Abstract][Full Text] [Related]
8. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
9. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
Greish K
J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
[TBL] [Abstract][Full Text] [Related]
10. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
11. Imaging-assisted anticancer nanotherapy.
Dasgupta A; Biancacci I; Kiessling F; Lammers T
Theranostics; 2020; 10(3):956-967. PubMed ID: 31938045
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting the dynamics and heterogeneity of the EPR effect: pathophysiological and pathoanatomic features, drug formulations and physicochemical factors.
Islam R; Maeda H; Fang J
Expert Opin Drug Deliv; 2022 Feb; 19(2):199-212. PubMed ID: 33430661
[TBL] [Abstract][Full Text] [Related]
13. Transcytosis-enabled active extravasation of tumor nanomedicine.
Zhou Q; Li J; Xiang J; Shao S; Zhou Z; Tang J; Shen Y
Adv Drug Deliv Rev; 2022 Oct; 189():114480. PubMed ID: 35952830
[TBL] [Abstract][Full Text] [Related]
14. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
[TBL] [Abstract][Full Text] [Related]
15. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicines for the treatment of hematological malignancies.
Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
[TBL] [Abstract][Full Text] [Related]
17. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
Durymanov MO; Rosenkranz AA; Sobolev AS
Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316
[TBL] [Abstract][Full Text] [Related]
18. Platinum-based combination nanomedicines for cancer therapy.
Li Y; Lin W
Curr Opin Chem Biol; 2023 Jun; 74():102290. PubMed ID: 36989943
[TBL] [Abstract][Full Text] [Related]
19. Reduction-sensitive polymeric nanomedicines: An emerging multifunctional platform for targeted cancer therapy.
Sun H; Zhang Y; Zhong Z
Adv Drug Deliv Rev; 2018 Jul; 132():16-32. PubMed ID: 29775625
[TBL] [Abstract][Full Text] [Related]
20. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.
Maeda H; Tsukigawa K; Fang J
Microcirculation; 2016 Apr; 23(3):173-82. PubMed ID: 26237291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
